Alnylam gets FDA nod for first-ever RNAi drug

The U.S. FDA has approved Alnylam Pharmaceuticals ’ Onpattro, making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis.

Source: PharmaManufacturing.com - August 13, 2018 Category: Pharmaceuticals Source Type: news